Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression / Claudia Bartels en The American Journal of Psychiatry, Año 2018 - Vol. 175 - No. 3 (Marzo)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2018 - Vol. 175 - No. 3 (Marzo) . - pp. 232-241 Título : Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression Tipo de documento: texto impreso Autores: Claudia Bartels, Autor ; Michael Wagner, Autor ; Steffen Wolfsgruber, Autor Fecha de publicación: 2018 Artículo en la página: pp. 232-241 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Enfermedad demencia-Alzheimer, Demencia, Diagnosis, clasificación, Psiquiatría geriátrica, Psicoterapia Resumen: Depression is associated with an increased risk of Alzheimer’s disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer’s dementia. Link: ./index.php?lvl=notice_display&id=13297 [artículo] Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression [texto impreso] / Claudia Bartels, Autor ; Michael Wagner, Autor ; Steffen Wolfsgruber, Autor . - 2018 . - pp. 232-241. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2018 - Vol. 175 - No. 3 (Marzo) . - pp. 232-241 Palabras clave: Enfermedad demencia-Alzheimer, Demencia, Diagnosis, clasificación, Psiquiatría geriátrica, Psicoterapia Resumen: Depression is associated with an increased risk of Alzheimer’s disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer’s dementia. Link: ./index.php?lvl=notice_display&id=13297

---

1 (1 - 1 / 1)